Albireo to Participate in Upcoming Investor Conferences
01 September 2022 - 10:00PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators to treat pediatric and adult
liver diseases, today announced participation in upcoming investor
conferences:
- Wells Fargo Securities
Healthcare Conference on Thursday, September 8, 2022Simon
Harford, Chief Financial Officer, and Colleen Alabiso, SVP,
Corporate Affairs, will host meetings with investors.
- Morgan Stanley 20th Annual Global Healthcare
Conference on Monday, September 12, 2022 Ron Cooper,
President and Chief Executive Officer, will be participating in a
fireside chat from 10:30 – 11:00 am ET. Ron Cooper and Simon
Harford will host meetings with investors.
- H.C. Wainwright 24th Annual Global Investment
Conference September 12-14, 2022 Pamela Stephenson, Chief
Commercial Officer, will participate in a fireside chat available
on September 12 at 7:00 am ET. Pamela Stephenson and Christine
Clemson, SVP, Head of Global Medical Affairs, will conduct investor
meetings on September 12.
- Baird 2022 Global Healthcare Conference on
Tuesday, September 13, 2022 Ron Cooper will be presenting from 8:30
– 9:00 am ET. Ron Cooper and Simon Harford will host meetings with
investors.
A replay of all webcasts will be available on-demand on the
Albireo Investors page ir.albireopharma.com.
About Albireo
Albireo Pharma is a rare disease company focused on the
development of novel bile acid modulators to treat pediatric and
adult liver diseases. Albireo’s lead product, Bylvay, was approved
by the U.S. FDA as the first drug for the treatment of pruritus in
all types of progressive familial intrahepatic cholestasis (PFIC),
and in Europe, Bylvay has been approved for the treatment of
PFIC. Bylvay is also being developed to treat other rare pediatric
cholestatic liver diseases with global Phase 3 trials in Alagille
syndrome (ALGS) and biliary atresia, as well as Open-label
Extension (OLE) studies for PFIC and ALGS. The Company has also
completed a Phase 1 clinical trial for A3907 to advance development
in adult cholestatic liver disease, with IND-enabling studies
progressing with A2342 for viral and cholestatic liver disease.
Albireo was spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating subsidiary in
Gothenburg, Sweden. For more information on Albireo, please visit
www.albireopharma.com.
Media Contacts:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2024 to May 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From May 2023 to May 2024